Powered by
-Boehringer Ingelheim expands collaboration with Vanderbilt University to tackle some of the most difficult-to-treat cancers

Ingelheim, Germany - Boehringer Ingelheim announced today a new collaboration with Vanderbilt University, Nashville, Tennessee.

The multi-year program complements an already existing collaboration by focusing on the research and development of small molecule compounds targeting the protein SOS (Son Of Sevenless).

This molecule activates KRAS, a molecular switch that plays a central role in the onset of some of the deadliest cancers.

The collaboration combines pioneering researc

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox